OTCMKTS:ESALY Eisai (ESALY) Stock Price, News & Analysis → “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad) Free ESALY Stock Alerts $61.51 -1.33 (-2.11%) (As of 01/30/2023) Add Compare Share Share Today's Range$61.00▼$63.2950-Day Range$61.51▼$61.5152-Week Range$36.88▼$73.90Volume331,800 shsAverage Volume60,916 shsMarket Capitalization$17.64 billionP/E Ratio70.70Dividend Yield1.43%Price TargetN/A Stock AnalysisStock Analysis Get Eisai alerts: Email Address Ad Stansberry Research“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.Find out why right here (and see what you can do to get in too with just a few dollars). About Eisai Stock (OTCMKTS:ESALY)Eisai Co., Ltd. engages in the development, manufacture, and sale of prescription medicines and over-the-counter products. It operates through the Pharmaceutical Products Business and Other Business segments. The Pharmaceutical Products Business segment handles prescription and generic drugs, diagnostics, and consumer healthcare business in Japan, which manages over-the-counter drugs. The Other Business segment deals with food additives and chemicals. The company was founded by Toyoji Naito in November 1936 and is headquartered in Tokyo, Japan.Read More ESALY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ESALY Stock News HeadlinesMarch 29, 2024 | wsj.comEisai Co. Ltd. ADRMarch 23, 2024 | reuters.comEisai Co LtdApril 26, 2024 | Stansberry Research (Ad)“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.March 20, 2024 | morningstar.comEisai Co Ltd 4523February 15, 2024 | finance.yahoo.comBIIB Mar 2024 210.000 callFebruary 15, 2024 | finance.yahoo.comBIIB Mar 2024 235.000 callFebruary 15, 2024 | finance.yahoo.comBIIB Feb 2024 227.500 callFebruary 14, 2024 | finance.yahoo.comBIIB Mar 2024 205.000 putApril 26, 2024 | Stansberry Research (Ad)“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.January 12, 2024 | seekingalpha.comESALF Eisai Co., Ltd.December 8, 2023 | markets.businessinsider.comMerck Says Phase 3 LEAP-001 Trial Evaluating KEYTRUDA Plus LENVIMA Did Not Meet EndpointsSeptember 25, 2023 | msn.comJapan's Regulatory Authority Approves Biogen/Eisai's Alzheimer Treatment LeqembiSeptember 22, 2023 | msn.comMerck-Eisai Partnered Two Keytruda/Lenvima Combo Trials Flunk In Certain Types Of Lung CancerJuly 6, 2023 | markets.businessinsider.comFDA Grants Traditional Approval To Eisai's Leqembi To Treat Adult Patients With Alzheimer's DiseaseJune 13, 2023 | benzinga.comAlzheimer's Drug Leqembi Faces Hurdles in Europe: Concerns Over Health Risks and Healthcare ResourcesJune 11, 2023 | markets.businessinsider.comFDA Panel Recommends Full Approval For Biogen And Eisai's Alzheimer's Drug LeqembiJune 8, 2023 | msn.comBernie Sanders Takes on High Costs of Alzheimer's Treatment Leqembi, Calls Price Tag 'Unconscionable'January 9, 2023 | finance.yahoo.comUTHR or ESALY: Which Is the Better Value Stock Right Now?January 6, 2023 | finance.yahoo.comFDA approves treatment for people with mild forms of Alzheimer’sNovember 30, 2022 | finance.yahoo.comDespite Safety Concerns, Analysts Are Bullish On Biogen's Second Alzheimer's CandidateNovember 30, 2022 | seekingalpha.comBiogen rallies Alzheimer’s drug developers after full data for lecanemabNovember 30, 2022 | finance.yahoo.comOpen Questions On Safety Lingers After Eisai-Biogen's Detailed Lecanemab Data For Alzheimer'sNovember 30, 2022 | seekingalpha.comBiogen's lecanemab shows less cognitive decline with Alzheimer's, but more brain swellingNovember 30, 2022 | barrons.comBiogen and Eisai’s Alzheimer’s Data Confirm Benefit. Questions Still Loom.November 28, 2022 | seekingalpha.comBiogen drops after report on second death linked to Alzheimer’s candidateNovember 28, 2022 | finance.yahoo.comUTHR vs. ESALY: Which Stock Is the Better Value Option?November 17, 2022 | msn.comAfter Rallying 50% in the Last 2 Months, Is Biogen Stock Still a Buy?See More Headlines Receive ESALY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eisai and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/04/2021Today4/26/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Private households Sub-IndustryN/A Current SymbolOTCMKTS:ESALY CUSIPN/A CIK948406 Webwww.eisai.co.jp Phone(133) 817-3700Fax813-3811-6032Employees11,322Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$0.87 Trailing P/E Ratio70.70 Forward P/E Ratio32.37 P/E Growth2.46Net Income$426.79 million Net Margins4.11% Pretax MarginN/A Return on Equity3.86% Return on Assets2.50% Debt Debt-to-Equity Ratio0.10 Current Ratio2.20 Quick Ratio1.77 Sales & Book Value Annual Sales$6.74 billion Price / Sales2.62 Cash Flow$2.68 per share Price / Cash Flow22.94 Book Value$23.94 per share Price / Book2.57Miscellaneous Outstanding Shares286,770,000Free FloatN/AMarket Cap$17.64 billion OptionableNot Optionable Beta0.31 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesHaruo NaitoChief Executive Officer & DirectorYasushi OkadaCOO, Representative Executive Officer & Head-ChinaTatsuyuki YasunoChief Financial & investor Relations OfficerKeisuke NaitoExecutive Officer & Head-Global IT HeadquartersYosuke AkitaChief Compliance Officer & & Head-Internal ControlKey CompetitorsShionogi & Co., Ltd.OTCMKTS:SGIOYSandoz GroupOTCMKTS:SDZNYH. Lundbeck A/SOTCMKTS:HLUYYEurofins ScientificOTCMKTS:ERFSFSysmexOTCMKTS:SSMXYView All Competitors ESALY Stock Analysis - Frequently Asked Questions Should I buy or sell Eisai stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Eisai in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ESALY shares. View ESALY analyst ratings or view top-rated stocks. How have ESALY shares performed in 2024? Eisai's stock was trading at $61.51 at the beginning of the year. Since then, ESALY stock has increased by 0.0% and is now trading at $61.51. View the best growth stocks for 2024 here. How were Eisai's earnings last quarter? Eisai Co., Ltd. (OTCMKTS:ESALY) released its earnings results on Wednesday, August, 4th. The company reported $1.34 earnings per share for the quarter, topping the consensus estimate of $1.09 by $0.25. The firm earned $1.82 billion during the quarter. Eisai had a trailing twelve-month return on equity of 3.86% and a net margin of 4.11%. Is Eisai a good dividend stock? Eisai (OTCMKTS:ESALY) pays an annual dividend of $0.88 per share and currently has a dividend yield of 1.43%. The dividend payout ratio is 101.15%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, ESALY will have a dividend payout ratio of 73.95% next year. This indicates that the company will be able to sustain or increase its dividend. How do I buy shares of Eisai? Shares of ESALY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:ESALY) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eisai Co., Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
